切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2018, Vol. 12 ›› Issue (02) : 139 -144. doi: 10.3877/cma.j.issn.1674-0793.2018.02.018

所属专题： 文献；

循证医学

长链非编码RNA低表达与胃癌患者预后关系的Meta分析
龙勃1, 王科深1, 任彦先1, 马志坚1, 俞泽元1, 焦作义1,†()   
  1. 1. 730030　兰州大学第二医院普外一科
  • 收稿日期:2017-12-24 出版日期:2018-04-01
  • 通信作者: 焦作义
  • 基金资助:
    国家自然科学基金资助项目(31670847); 甘肃省卫生行业科研计划项目(GSWSK2016-03)

A meta-analysis of the relationship between low expression of long non-coding RNA and prognosis of gastric cancer patients

Bo Long1, Keshen Wang1, Yanxian Ren1, Zhijian Ma1, Zeyuan Yu1, Zuoyi Jiao1,†()   

  1. 1. The First Department of General Surgery, the Second Hospital Affiliated to Lanzhou University, Lanzhou 730030, China
  • Received:2017-12-24 Published:2018-04-01
  • Corresponding author: Zuoyi Jiao
  • About author:
    Corresponding author: Jiao Zuoyi, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

龙勃, 王科深, 任彦先, 马志坚, 俞泽元, 焦作义. 长链非编码RNA低表达与胃癌患者预后关系的Meta分析[J/OL]. 中华普通外科学文献(电子版), 2018, 12(02): 139-144.

Bo Long, Keshen Wang, Yanxian Ren, Zhijian Ma, Zeyuan Yu, Zuoyi Jiao. A meta-analysis of the relationship between low expression of long non-coding RNA and prognosis of gastric cancer patients[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2018, 12(02): 139-144.

目的

对胃癌组织中长链非编码RNA（LncRNA）表达水平与患者临床病理特征关系及预后价值进行系统性评价。

方法

计算机检索中国学术期刊全文数据库（CNKI）、中国生物医学文献数据库（CBMdisc）、万方数据库、重庆维普数据库和英文数据库EMbase、PubMed、The Cochrane Library（2017年4期）、Web of Science，查找建库至2017年4月发表的有关胃癌组织中LncRNA低表达与患者预后的研究。经2名研究人员独立地进行筛选文献、提取数据、质量评价后，采用STATA 12.0软件对数据行Meta分析，Begg's和Egger's漏斗图评价发表偏倚。

结果

共纳入6篇594例胃癌患者LncRNA低表达的研究，组织样本均来自于国内。胃癌患者的LncRNA表达水平与TNM分期（RR=2.06，95% CI =1.73~2.46，P=0.001）、肿瘤浸润深度（RR=2.73，95% CI =2.17~2.43，P=0.001）和区域淋巴结转移（RR=1.63，95% CI =1.37~1.94，P=0.001）相关，而其他临床病理特征与LncRNA表达水平无相关关系，差异无统计学意义。5篇报道胃癌患者总生存期（OS）的研究间存在统计学异质性（I2=68.9%，P=0.012），分析显示与LncRNA高表达组相比，LncRNA低表达组患者的OS较短，总体生存情况较差，差异有统计学意义（HR=0.56，95% CI =0.31~0.99，P=0.046）。3篇报道无疾病进展生存期（DFS）的研究存在统计学异质性（I2=71.0%，P=0.032），分析显示LncRNA高表达组和低表达组间DFS差异无统计学意义（HR=0.57, 95% CI=0.32~1.03，P=0.061）。各项研究对合并OS影响的敏感性分析结果显示合并HR的结果稳定性好，发表偏倚可能性较小（Egger's，P=0.651；Begg's，P=0.806）。

结论

低表达的LncRNA是胃癌预后不良的危险因素，LncRNA的表达水平与胃癌患者的TNM分期、肿瘤的浸润深度和区域淋巴结转移密切相关。

关键词: 胃肿瘤, 长链非编码RNA, 预后, Meta分析
Objective

To systematically evaluate whether the expression level of LncRNA is associated with the clinicopathological features and prognostic value for gastric cancer.

Methods

The Chinese databases including CNKI, CBM, WanFang Databases, VIP Databases, and the English databases including EMbase, PubMed, Cochrane Library (Issue 4, 2017) and Web of Science were systematically searched with the search time end in April 2017. All eligible studies associated with downregulated LncRNA and prognosis in gastric cancer were included. Two researchers independently screened the included studies, extracted data and evaluated the quality. The STATA 12.0 software and Begg's, Egger's funnel maps were used for Meta-analysis and evaluation of publication bias.

Results

A total of six studies about 594 gastric cancer patients which showed the relationship between the low expression level of LncRNA were finally included, and all the tissue samples were from China. The expression level of LncRNA was associated with TNM staging (RR=2.06, 95% CI=1.73-2.46, P=0.001) , the depth of invasion (RR=2.73, 95% CI =2.17-2.43, P=0.001) and the number of lymph node metastases (RR=1.63, 95% CI=1.37-1.94, P=0.001) . There was significant difference in overall survival among the 5 groups (I2=68.9%, P=0.012) , whereas low-regulated LncRNA which showed a shorter overall survival (HR=0.56, 95% CI=0.31-0.99, P=0.046) was statistically significant. There was significant difference in disease free survival among the three studies (I2=71.0%, P=0.032) , while no significant difference between the high-expression group and the low-expression group of LncRNA (HR=0.57, 95% CI=0.32-1.03, P=0.061) . The effects of the 6 studies on the combination of HR and the possibility of publishing bias were small (Egger's, P=0.651; Begg's, P=0.806) .

Conclusions

Low expression of LncRNA is a predictive risk factor for poor prognosis in gastric cancer patients. The expression level of LncRNA is closely related to TNM stage, depth of tumor invasion and regional lymph node metastasis in patients with gastric cancer.

Key words: Stomach neoplasms, Long non-coding RNA, Prognosis, Meta-analysis
图1 PubMed检索策略
图2 文献筛选流程及结果
表1 纳入研究的基本特征
作者，发表年 地区 样本总量 LncRNA名称 方法 截点值 TNM分期 提取方法 结局指标
Fan 2016[12] 中国 138 LINC00261 RT-qPCR 中值 Ⅰ-Ⅳ 文中 DFS
Fei 2016[13] 中国 106 LINC00982 RT-qPCR 中值 Ⅰ-Ⅳ 文中 OS、DFS
Lai 2015[14] 中国 89 ZMAT1 RT-qPCR 中值 Ⅰ-Ⅳ 生存曲线 OS
Sun 2015[15] 中国 96 RP11-119F7.4 RT-qPCR 中值 Ⅰ-Ⅲ 生存曲线 OS、DFS
Sun 2014[16] 中国 72 MEG3 RT-qPCR 中值 Ⅱ-Ⅳ 生存曲线 OS
Zhou 2014[17] 中国 93 LET RT-qPCR 中值 Ⅰ-Ⅳ 文中 OS
表2 纳入研究质量评价结果
作者，发表年 研究对象 减员偏倚 预后因素测量 结局测量 混杂因素的测量和计算 分析方法
Fan 2016[12] 是 是 部分 是 部分 是
Fei 2016[13] 部分 是 是 部分 部分 是
Lai 2015[14] 否 是 是 部分 部分 是
Sun 2015[15] 是 是 部分 是 部分 是
Sun 2014[16] 是 是 是 是 部分 是
Zhou 2014[17] 是 是 是 是 部分 是
表3 纳入研究中LncRNA低表达与临床病理特征的Meta分析结果
临床特征 篇数（n） 异质性检验 效应模型 Meta分析
I2（%）值 P值 RR（95% CI） P值
年龄（≤50岁） 3 57.1 0.097 随机 1.01（0.72~1.43） 0.938
肿瘤大小 5 66.3 0.018 随机 1.13（0.81~1.58） 0.468
肿瘤位置 3 38.2 0.183 固定 1.03（0.88~1.21） 0.690
TNM分期 5 33.1 0.201 固定 2.06（1.73~2.46） 0.001
性别 5 1.1 0.400 固定 0.96（0.83~1.12） 0.642
远处转移 5 79.2 0.001 随机 0.84（0.40~1.75） 0.642
淋巴结站转移 5 89.2 0.001 随机 0.79（0.45~1.40） 0.418
病理分化程度 4 38.2 0.183 固定 1.05（0.82~1.34） 0.691
肿瘤浸润深度 5 0 0.606 固定 2.73（2.17~3.43） 0.001
区域淋巴结转移 3 0 0.715 固定 1.63（1.37~1.94） 0.001
图3 LncRNA低表达与OS关系的Meta分析结果
图4 LncRNA低表达与DFS关系的Meta分析结果
图5 纳入的研究文献敏感性分析图
[1]
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[2]
陈万青，郑荣寿，张思维, 等. 2012年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2015, 25(1): 1-8.
[3]
季加孚. 我国胃癌防治研究三十年回顾[J]. 中国肿瘤临床, 2013, 40(22): 1345-1351.
[4]
Zoalfaghari A, Aletaha N, Roushan N, et al. Accuracy of pepsinogens for early diagnosis of atrophic gastritis and gastric cancer in Iranian population[J]. Med J Islam Repub Iran, 2014, 28: 150.
[5]
Kwee RM, Kwee TC. Predicting lymph node status in early gastric cancer[J]. Gastric Cancer, 2008, 11(3): 134-148.
[6]
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018 Jan 30. pii: S0140-6736(17)33326-3.
[7]
Li PF, Chen SC, Xia T, et al. Non-coding RNAs and gastric cancer[J]. World J Gastroenterol, 2014, 20(18): 5411-5419.
[8]
Ørom UA, Shiekhattar R. Long non-coding RNAs and enhancers[J]. Curr Opin Genet Dev, 2011, 21(2): 194-198.
[9]
Hajjari M, Behmanesh M, Sadeghizadeh M, et al. Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues[J]. Med Oncol 2013, 30(3): 670.
[10]
Zhuang M, Gao W, Xu J, et al. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1[J]. Biochem Biophys Res Commun, 2014, 448(3): 315-322.
[11]
Zuo ZK, Gong Y, Chen XH, et al. TGFβ1-induced LncRNA UCA1 upregulation promotes gastric cancer invasion and migration[J]. DNA Cell Biol, 2017, 36(2): 159-167.
[12]
Fan Y, Wang YF, Su HF, et al. Decreased expression of the long noncoding RNA LINC00261 indicate poor prognosis in gastric cancer and suppress gastric cancer metastasis by affecting the epithelial-mesenchymal transition[J]. J Hematol Oncol, 2016, 9(1): 57.
[13]
Fei ZH, Yu XJ, Zhou M, et al. Upregulated expression of long non-coding RNA LINC00982 regulates cell proliferation and its clinical relevance in patients with gastric cancer[J]. Tumour Biol, 2016, 37(2): 1983-1993.
[14]
Lai Y, Xu P, Li Q, et al. Downregulation of long noncoding RNA ZMAT1 transcript variant 2 predicts a poor prognosis in patients with gastric cancer[J]. Int J Clin Exp Pathol, 2015, 8(5): 5556-5562.
[15]
Sun J, Song Y, Chen X, et al. Novel long non-coding RNA RP11-119f7.4 as a potential biomarker for the development and progression of gastric cancer[J]. Oncol Lett, 2015, 10(1): 115-120.
[16]
Sun M, Xia R, Jin F, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer[J]. Tumour Biol, 2014, 35(2): 1065-1073.
[17]
Zhou B, Jing XY, Wu JQ, et al. Down-regulation of long non-coding RNA LET is associated with poor prognosis in gastric cancer[J]. Int J Clin Exp Pathol, 2014, 7(12): 8893-8898.
[18]
周支瑞，张天嵩，李博, 等. 生存曲线中Meta分析适宜数据的提取与转换[J]. 中国循证心血管医学杂志, 2014, (3): 243-247.
[19]
Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews[J]. Ann Intern Med, 2006, 144(6): 427-437.
[20]
Zhang EB, Han L, Yin DD, et al. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer[J]. Med Oncol, 2014, 31(5): 914.
[21]
Xu ZY, Yu QM, Du YA, et al. Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer[J]. Int J Biol Sci, 2013, 9(6): 587-597.
[22]
Park SM, Park SJ, Kim HJ, et al. A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis[J]. Exp Mol Med, 2013, 45(7): e31.
[23]
Xie M, Sun M, Zhu YN, et al. Long noncoding RNA HOXA-AS2 promotes gastric cancer proliferation by epigenetically silencing P21/PLK3/DDIT3 expression[J]. Oncotarget, 2015, 6(32): 33587-33601.
[24]
Wang J, Sun J, Wang J, et al. Long noncoding RNAs in gastric cancer: functions and clinical applications[J]. Onco Targets Ther, 2016, 9(1): 681-697.
[25]
Liu L, Yan B, Yang Z, et al. ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1[J]. Tumour Biol, 2014, 35(8): 7821-7829.
[26]
Shao Y, Chen H, Jiang X, et al. Low expression of LncRNA-HMlincRNA717 in human gastric cancer and its clinical significances[J]. Tumour Biol, 2014, 35(10): 9591-9595.
[27]
Peng W, Si S, Zhang Q, et al. Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression[J]. J Exp Clin Cancer Res, 2015, 34(1): 79.
[28]
Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17): 3850-3856.
[29]
Liu Z, Shao Y, Tan L, et al. Clinical significance of the low expression of FER1L4 in gastric cancer patients[J]. Tumour Biol, 2014, 35(10): 9613-9617.
[30]
Xu TP, Huang MD, Xia R, et al. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression[J]. J Hematol Oncol, 2014, 7: 63.
[31]
Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis[J]. Mol Cancer, 2016, 15(1): 50.
[32]
Cui Z, Chen Y, Xiao Z, et al. Long noncoding RNAs as auxiliary biomarkers for gastric cancer screening: A pooled analysis of individual studies[J]. Oncotarget, 2016, 7(18): 25791-25800.
[33]
李幼平，李静，孙鑫, 等. 循证医学在中国的起源与发展:献给中国循证医学20周年[J]. 中国循证医学杂志, 2016, 16(1): 2-6.
[1] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[2] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[7] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[8] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[9] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[10] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[11] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[14] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[15] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号